Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.82% | -4.38% | -12.03% | -11.23% | -10.43% |
| Total Depreciation and Amortization | 35.23% | 51.58% | 34.50% | 18.28% | 1.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.35% | -24.01% | -16.97% | -23.77% | -19.67% |
| Change in Net Operating Assets | 137.72% | 140.23% | 124.39% | 128.75% | 7.28% |
| Cash from Operations | 3.12% | 3.90% | 0.65% | -2.91% | -18.22% |
| Capital Expenditure | 82.55% | 78.25% | 33.74% | 23.66% | -4.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 760.15% | 392.15% | 303.00% | 363.01% | -130.21% |
| Cash from Investing | 665.52% | 360.32% | 284.78% | 332.47% | -136.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.68% | -99.68% | -77.05% | -77.01% | 19,666.09% |
| Repurchase of Common Stock | -30.30% | -217.65% | -200.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -137.04% | -- | -- | -- | 200.00% |
| Cash from Financing | -100.19% | -100.09% | -77.41% | -77.22% | 34,670.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.19% | -141.19% | 86.82% | 105.70% | 119.46% |